It is also unclear from experimental studies in animal models whether the apelin signalling pathway should be blocked by the addition of apelin antagonist or whether low levels of the endogenous peptide should be enhanced as in PAH. This evidence concerns the gene APLN and pulmonary arterial hypertension.